We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
A Sweden-based pharmaceutical company Staybe Therapeutics partnered with OCT Clinical, a leading CRO in Eastern Europe, to run a Phase 2b study in three European countries.
This is a multicenter, randomized Phase 2b study, the primary goal of which is to evaluate the efficacy of the study medicine vs. placebo. The study is double-blinded, which means that neither the patient nor the treating physician knows whether the patient is receiving a high or low dose of STA363 - the medicine under study - or a placebo. All trial participants are followed-up for 12 months.
Download the full text of this case study to learn more about the project.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
